Search results
Results from the WOW.Com Content Network
Bio-Rad (BIO) Q4 earnings are expected to have benefited from strong sales, particularly within core PCR products, Droplet Digital PCR and Process Media.
Robust uptake of dPCR products and a rebound in routine testing are likely to have contributed to Bio-Rad's (BIO) Q4 top line.
Report of Test Results 865 Purchase Order Change Acknowledgment/Request - Seller Initiated 866 Production Sequence 867 Product Transfer and Resale Report 869 Order Status Inquiry 870 Order Status Report 871 Component Parts Content 873 Commodity Movement Services 874 Commodity Movement Services Response 875 Grocery Products Purchase Order 876
Bio-Rad's (BIO) Clinical Diagnostics segment is expected to report growth in Q2, driven by its focus on laboratory workflow productivity, quality control, and new opportunities in molecular ...
Purchase Order 850 ORDERS Purchase Order Acknowledgement 855 ORDRSP Purchase Order Change 860 ORDCHG Purchase Order Change Acknowledgement 865 ORDRSP Order Status Inquiry 869 ORSSTA Order Status Report 870 ORDREP Contract Award 836 — Product Activity Data 852 SLSRPT MATERIALS MANAGEMENT TRANSACTIONS Planning Schedule/Material Release 830 DELFOR
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, California , by husband and wife team David and Alice Schwartz , both graduates of the University of California, Berkeley.
Improvement in demand at non-COVID business and continued strength in Bio-Rad's (BIO) Life Science segment are likely to have contributed to Q2 results.
This page was last edited on 14 August 2009, at 22:44 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may ...